Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Champions Oncology Inc (CSBR)
NASDAQ:CSBR
Holding CSBR?
Track your performance easily
CSBR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.60 - $7.13
Previous Close$4.28
Volume42.28K
Average Volume (3M)49.74K
Market Cap
$64.98M
Enterprise Value$62.40M
Total Cash (Recent Filing)$2.89M
Total Debt (Recent Filing)$7.11M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Dec 10, 2024EPS Estimate
$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding13,593,767
10 Day Avg. Volume274,164
30 Day Avg. Volume49,741
Standard Deviation0.13
R-Squared0.03
Alpha-0.00203
Financial Highlights & Ratios
Price to Book (P/B)-214.00
Price to Sales (P/S)1.21
Price to Cash Flow (P/CF)50.30
P/FCF Ratio49.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.21
Enterprise Value/Gross Profit3.01
Enterprise Value/Ebitda-38.88
Forecast
1Y Price Target
$6.00Price Target Upside25.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Champions Oncology News
Ownership Overview
51.07% Insiders
3.25% Mutual Funds
37.82% Other Institutional Investors
7.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CSBR FAQ
What was Champions Oncology Inc’s price range in the past 12 months?
Champions Oncology Inc lowest stock price was $3.60 and its highest was $7.13 in the past 12 months.
What is Champions Oncology Inc’s market cap?
Currently, no data Available
When is Champions Oncology Inc’s upcoming earnings report date?
Champions Oncology Inc’s upcoming earnings report date is Dec 10, 2024 which is in 81 days.
How were Champions Oncology Inc’s earnings last quarter?
Champions Oncology Inc released its earnings results on Sep 11, 2024. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of -$0.03 by $0.14.
Is Champions Oncology Inc overvalued?
According to Wall Street analysts Champions Oncology Inc’s price is currently Undervalued.
Does Champions Oncology Inc pay dividends?
Champions Oncology Inc does not currently pay dividends.
What is Champions Oncology Inc’s EPS estimate?
Champions Oncology Inc’s EPS estimate is $0.01.
How many shares outstanding does Champions Oncology Inc have?
Champions Oncology Inc has 13,593,767 shares outstanding.
What happened to Champions Oncology Inc’s price movement after its last earnings report?
Champions Oncology Inc reported an EPS of $0.11 in its last earnings report, beating expectations of -$0.03. Following the earnings report the stock price went up 9.582%.
Which hedge fund is a major shareholder of Champions Oncology Inc?
Currently, no hedge funds are holding shares in CSBR
---
Champions Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.69%
12-Months-Change
Fundamentals
Return on Equity
-432.46%
Trailing 12-Months
Asset Growth
-16.63%
Trailing 12-Months
Company Description
Champions Oncology Inc
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
---
CSBR Earnings Call
Q1 2024
0:00 / 0:00
---
CSBR Stock 12 Month Forecast
Average Price Target
$6.00
▲(25.52% Upside)
Technical Analysis
Plus Therapeutics
―
TFF Pharmaceuticals
―
Protara Therapeutics
―
Aspira Women's Health
―
Best Analysts Covering CSBR
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
-9.55%
reiterated a buy rating 12 months ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -9.55% per trade.
---